Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer

Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer

Background The impact of primary tumor size on the therapeutic outcomes of EGFR‐tyrosine kinase inhibitors (TKIs) in advanced non‐small cell lung cancer (NSCLC) with EGFR mutation remains unclear. Methods A total of 291 consecutive patients with advanced EGFR‐mutant NSCLC administered first‐line EGF...

Full description

Bibliographic Details
Main Authors: Yingying Pan, Guanghui Gao, Xiaoxia Chen, Qinrui Tian, Fengying Wu, Qian Liu, Yan Wang, Tao Jiang, Yiwei Liu, Xuefei Li, Shuo Yang, Chuan Xu, Chunxia Su, Fei Zhou, Shengxiang Ren, Caicun Zhou
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:Thoracic Cancer
Subjects:
Adenocarcinoma
efficacy
EGFR‐TKIs
tumor size
Online Access:https://doi.org/10.1111/1759-7714.12986

Internet

https://doi.org/10.1111/1759-7714.12986

Similar Items